Investigation into ADMA Biologics' Board for Potential Fiduciary Duty Breach
Berger Montague PC has launched an investigation targeting the board of directors at ADMA Biologics, Inc. (NASDAQ: ADMA) over potential breaches of fiduciary duty related to alleged channel-stuffing practices aimed at boosting revenue growth for its flagship product, ASCENIV. The firm is examining whether these tactics were used despite declining demand for the drug, which treats Primary Humoral Immunodeficiency. ADMA Biologics operates as a biopharmaceutical company specializing in specialty biologics and immune globulin therapies. Shareholders are being urged to contact Berger Montague with any relevant information or concerns about this matter.
Tickers: $ADMA
Topics: corporate_governance securities_law